Infosys Buys Optimum For US$465 Million To Scale Healthcare IT

Recently, Infosys, India’s tech giant and a global leader in next-generation technology, announced its acquisition of Optimum Healthcare IT, one of the largest healthcare IT services companies, for US$465 million. According to sources, the deal is expected to be completed by June and will be an all-cash transaction. It includes upfront costs and earn-outs but excludes management incentives and retention bonuses.

Apart from this acquisition, Infosys is also planning to invest in Stratus Global, a New Jersey-based technology services firm catering to the insurance sector, in a deal valued at up to US$95 million.

Why Is Infosys Investing In Optimum Healthcare IT?

Healthcare has silently climbed into the priority verticals of the major IT companies because of the ageing population, the digitisation of medical records and regulatory changes. This is where companies like Optimum Healthcare IT step in with their deep expertise and solid client relationships.

Apart from this, Optimum specialises in some of the critical and complex aspects of healthcare IT, which include electronic health record (EHR) advisory, implementation, and support. This positions the company as a major player in the space.

How Does This Deal Strengthen Infosys’ AI And Cloud Strategy?

The acquisition is designed to integrate Optimum’s healthcare expertise with Infosys’ offerings, such as:

• Topaz (AI)

• Cobalt (cloud)

• Cloud engineering

• Infrastructure services

• Cybersecurity

This enables end-to-end digital transformation for healthcare providers. The deal positions Infosys to compete more aggressively with global peers like Accenture, Cognizant, and Oracle, all of whom are investing heavily in healthcare IT platforms and large-scale transformation programmes.

What Does The Twin Acquisition Strategy Signal?

This dual acquisition strategy signals a clear shift towards industry-specific platforms and consulting depth. This is especially true in emerging verticals like healthcare and insurance. It also reflects Infosys’ intent to build scalable, AI-driven service offerings across regulated, high-spend sectors in the US market.

Also Read - JPMorgan’s New Debt Product Is Sparking 2008 Comparisons

How Will This Impact Infosys Shares?

At 11:00 am on Friday, 27 March 2026, Infosys shares were trading at ₹1,275.80, down by 0.27%. However, the volatility is mostly due to broader market sentiment.

Turning back to the deal, Infosys expects it to add US$319 million to its incremental revenue, with US$276 million coming from Optimum Healthcare IT and US$43 million from Stratus, accounting for nearly 45% of the company’s incremental revenue in the previous year.

Sources

Infosys

The Hindu

Mint